OraSure Technologies CEO Carrie Eglinton Manner said in her presentation that the firm's recent $25 million acquisition of ...

Highlights from the third day included information about Quanterix's new Simoa One platform, expected to launch at the end of ...

Rounding out the other four largest financing rounds in 2024 are proteomics company Alamar Biosciences' $128 million Series C ...

The Dublin-based firm said that it will use the money for development for its rapid test to aid the diagnosis and treatment of sepsis.

The proteomic blood test could be a noninvasive tool used to improve detection of the condition, which currently takes an average of 7.5 years to diagnose.

The report also indicates that while PAMA has cut spending on routine tests, overall lab spending has risen as genetic testing continues to grow.

The firm will use its blood-based tests to explore connections between Alzheimer's disease and neuronal α-synuclein conditions including Parkinson's disease.

Tempus AI has launched the next-generation sequencing-based xT CDx test. The US Food and Drug Administration-approved test comprises 648 genes and is used to provide solid tumor profiling in cancer ...